Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA plus CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study

Siefker-Radtke, Arlene O.Powles, ThomasMoreno, VictorKang, Taek WonCicin, IrfanGirvin, AngelaAkapame, Sydney2024-06-122024-06-1220230732-183X1527-7755https://hdl.handle.net/20.500.14551/26770Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 02-06, 2023 -- Chicago, IL[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA plus CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse studyConference Object4116N/AWOS:001053772000991